Biomerieux receives Investment Bank Analyst Rating Update
Disappointing German PMI data sets up increased expectations of an ECB rate cutNotes/ObservationsChina Apr HSBC Flash PMI Manufacturing come in below expectations at 50.5 v 51.5e;...
Italy pays higher yield at BTP auction as Ruling Government has yet to be decidedNotes/Observations(CY) Cyprus and Troika said to be negotiating smaller bailout package at around...
UK Q4 GDP contracts; German IFO survey mixed; All eyes now on FOMC statement and forecastsEconomic Data(EU) ECB: €3.6B borrowed in overnight loan facility v €3.4B prior;...
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
|Average||105.75 (+13.56% Upside)|
|No. of Analysts||10|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Neutral|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Neutral|